Novel Anti-Glycan Antibodies Related to Inflammatory Bowel Disease Diagnosis and Phenotype

@article{Seow2009NovelAA,
  title={Novel Anti-Glycan Antibodies Related to Inflammatory Bowel Disease Diagnosis and Phenotype},
  author={Cynthia H. Seow and Joanne M. Stempak and Wei Gang Xu and Hui Lan and Anne M. Griffiths and Gordon R. Greenberg and A. Hillary Steinhart and Nir Dotan and Mark S. Silverberg},
  journal={The American Journal of Gastroenterology},
  year={2009},
  volume={104},
  pages={1426-1434}
}
OBJECTIVES:We sought to evaluate whether two novel immunoglobulin A (IgA) cell wall polysaccharide antibodies, anti-laminarin (anti-L) and anti-chitin (anti-C), aid in the diagnosis and phenotype differentiation of Crohn's disease (CD) and ulcerative colitis (UC).METHODS:A cohort of 818 individuals with inflammatory bowel disease (IBD; 517 CD and 301 UC) from two IBD tertiary referral centers, with median ages of 33 and 39 years, respectively, and disease duration of 8.9 years, were phenotyped… 
Characterization of Changes in Serum Anti-Glycan Antibodies in Crohn's Disease – a Longitudinal Analysis
TLDR
The ability of the panel to discriminate CD from UC or its association with CD phenotypes remained stable during follow-up, and the antibody status is widely stable over time.
New Serologic Markers for Inflammatory Bowel Disease Diagnosis
  • I. Dotan
  • Biology, Medicine
    Digestive Diseases
  • 2010
TLDR
The finding of antibodies against these glycans suggests a connection between the adaptive and innate arms of the immune response in CD patients, and their significance in diagnosing populations at risk, such as unaffected relatives of IBD patients and CD patients prior to diagnosis, is under current investigation.
Serum anti-glycan antibodies in paediatric-onset Crohn's disease: association with disease phenotype and diagnostic accuracy
TLDR
Qualitative and quantitative serologicalal response to glycan epitopes was associated with distinct clinical presentation in paediatric CD patients, raising the possibility for the use of these markers to differentiate subgroups of CD patients with more sever clinical presentation.
Clinical Utility of Anti‐Glycan Antibodies in Pediatric Crohn's Disease in Comparison with An Adult Cohort
TLDR
A panel of anti‐glycan antibodies including the novel Anti‐L and Anti‐C may aid in the differentiation of pediatric CD from UC and is associated with complicated CD behavior.
Serum Antibodies Associated with Complex Inflammatory Bowel Disease
TLDR
Increased serological markers are associated with a more aggressive CD phenotype and an increased need for colectomy in UC, which raises the possibility for use of these markers in patients at risk of complex disease.
The role of Anti-Saccharomyces cerevisiae Immunoglobulins ( IgG , IgA ) And Atypical Perinuclear Antineutrophilic Cytoplasmic Antibody In Diagnosis And Classification Of Inflammatory Bowel Disease
TLDR
ASA (IgG and IgA) and pANCA are useful tools for diagnosis and classification of IBDs if used in combination, but not alone.
Serum anti-glycan-antibodies in relatives of patients with inflammatory bowel disease
TLDR
Non-affected CD relatives had a higher frequency of anti-glycan antibodies compared to healthy subjects, which may indicate an inherited mechanism resulting in a non-specific increased reactivity to microbial antigens in IBD.
Serum anti‐glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: A systematic review and meta‐analysis
TLDR
Although in most individual studies the combination of ≥2 markers had a better diagnostic value as well as higher association with complications and need for surgery, the combination found the combination performing slightly better than any individual marker in the meta‐analysis.
Serological markers of inflammatory bowel disease
  • A. Kuna
  • Biology, Medicine
    Biochemia medica
  • 2013
TLDR
Current evidence suggests that serologic panels of multiple antibodies are useful in differential diagnosis of CD versus UC and can be a valuable aid in stratifying patients according to disease phenotype and risk of complications.
ASCA, ANCA, ALCA and Many More: Are They Useful in the Diagnosis of Inflammatory Bowel Disease?
TLDR
Serological biomarkers have been demonstrated to be a series of rapid, non-invasive approaches for assessments of early diagnosis, disease activity and prognosis for IBD and have limited values in making initially definite diagnosis for I BD.
...
...

References

SHOWING 1-10 OF 31 REFERENCES
Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease.
TLDR
Antilaminaribioside and antichitobioside carbohydrate antibodies are novel serologic markers associated with Crohn's disease that may contribute to the diagnosis and improved stratification of Crohn’s disease.
Anti-Glycan Antibodies as Biomarkers for Diagnosis and Prognosis
TLDR
Anti-glycan antibodies profiling (AGAP) is a new and promising approach for development of biomarkers for diagnosis and prognosis in MS and CD patients.
New serological markers in inflammatory bowel disease are associated with complicated disease behaviour
TLDR
The number and magnitude of immune responses to different microbial antigens were shown to be associated with the severity of the disease and the predictive role of serological markers are necessary.
Diagnostic Precision of Anti-Saccharomyces cerevisiae Antibodies and Perinuclear Antineutrophil Cytoplasmic Antibodies in Inflammatory Bowel Disease
TLDR
ASCA and pANCA testing are specific but not sensitive for CD and UC, and may be particularly useful for differentiating between CD andUC in the pediatric population.
Sero-Reactivity to Microbial Components in Crohn's Disease Is Associated with Disease Severity and Progression, but not NOD2/CARD15 Genotype
TLDR
Reactivity to microbial components is associated with severe CD characterized by small bowel involvement, frequent disease progression, longer disease duration, and greater need for intestinal surgery.
Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease
TLDR
ASA and pANCA may predict development of inflammatory bowel disease years before the disease is clinically diagnosed and measurements of the average time from the presence of ASCA to diagnosis may be even longer.
Anti-Saccharomyces Cerevisiae Antibodies (ASCA), Phenotypes of IBD, and Intestinal Permeability: A Study in IBD Families
TLDR
ASCA is strongly associated with familial CD in Belgium, and 21% of healthy family members also display the marker, while pANCA is much weaker in patients belonging to mixed families, and is not a secondary phenomenon due to increased intestinal permeability.
Comparative study of ASCA (Anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease.
TLDR
A large range in sensitivities and specificities of ASCA for CD is seen with different ASCA assays, mainly as a consequence of the cutoff value chosen for each individual assay.
Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease.
TLDR
Serum responses to CBir1 independently identify a unique subset of patients with complicated CD patients, and this bacterial antigen was identified in a murine model and has a similar pattern of aberrant reactivity in a subset of CD patients.
Utility of serological markers in inflammatory bowel diseases: gadget or magic?
TLDR
An increasing number of observations confirms that patients with Crohn's disease expressing multiple serologic markers at high titers are more likely to have complicated small bowel disease and are at higher risk for surgery than those without, or with low titers of antibodies.
...
...